Illumina Protein Prep: NGS-based Proteomics Discovery at Scale for Disease Treatment

Illumina Protein Prep, a new assay for next-generation sequencing (NGS) based proteomics discovery, can measure 9500 unique human protein targets. Following an early access program, customers have praised the scale, high consistency, and easy sample-to-insights workflow. The launch follows Illumina's announcement of an agreement to acquire SomaLogic and aims to fuel novel discoveries for disease treatment.

Illumina Inc. (NASDAQ: ILMN) has announced the launch of Illumina Protein Prep, a new assay designed for next-generation sequencing (NGS) based proteomics discovery. The tool can measure 9500 unique human protein targets, offering unprecedented insights into protein biology and fueling novel discoveries for disease treatment. Following an early access program, customers have commended the assay's scale, high consistency, and ease of use from sample to insights workflow [1].

The launch of Illumina Protein Prep comes after Illumina's announcement of an agreement to acquire SomaLogic, a leader in data-driven proteomics technology. This acquisition aims to enhance Illumina's presence in the expanding proteomics market and advance its multiomics strategy [2].

Illumina Protein Prep leverages SOMAmer™ technology to provide high analytical sensitivity and the ability to measure 9500 unique human protein targets, the most with an NGS readout. This capability enables researchers to interrogate thousands of proteins simultaneously in a single experiment, maximizing the discovery power of proteomics studies [1].

The assay combines the power of Illumina NovaSeq™ sequencing platforms and Illumina DRAGEN™ Protein Quantification and Connected Multiomics software to streamline analysis and accelerate progress from discovery to therapeutic development. Early access customers have processed over 30,000 samples with the Illumina Protein Prep 6K assay and over 6,000 samples with the Illumina Protein Prep 9.5K assay, demonstrating the tool's potential in large-scale proteomic studies [1].

Illumina Protein Prep is already being used in significant research projects, such as Genomics England's 100,000 Genomes Project, which has seen a 7.5% increase in diagnostic yield for rare diseases through proteomic profiling [1]. Additionally, researchers at the University of Colorado Anschutz Medical Campus are using Illumina Protein Prep to investigate rare melanomas, aiming to identify biomarkers for improved diagnostics and therapies [1].

The launch of Illumina Protein Prep is part of a broader initiative to drive innovation in proteomics and multiomics. Illumina's agreement to acquire SomaLogic further strengthens its position in the market and supports its multiomics strategy [2].

References:

[1] https://www.prnewswire.com/news-releases/illumina-protein-prep-launches-to-drive-greater-proteomic-insights-for-improved-drug-discovery-and-development-302544664.html
[2] https://ca.finance.yahoo.com/news/illumina-protein-prep-launches-drive-131500727.html